Entrada Therapeutics reports Q2 net loss of $43.1M; cash runway into Q2 2027; advances DMD trials

Entrada Therapeutics, Inc.

2025-Q2 EPS reported -$1.47 revenue$22,508,000

Net loss of $43.1M in Q2 2025 vs net income of $55.0M in Q2 2024; collaboration revenue fell from $94.7M to $2.0M.
Cash, cash equivalents and marketable securities $354M as of June 30, 2025; expected runway into Q2 2027.
First patient dosed in ELEVATE-44-201 for DMD exon 44; data from first cohort expected H1 2026.
Initiated ELEVATE-45-201 for exon 45; first patient dosing on track Q3 2025; cohort 1 data mid-2026.
Expanded leadership: Navid Khan as SVP Medical Affairs, Kiran Patki as SVP Clinical Development; Maha Radhakrishnan joined Board.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.